Xencor, Inc. (NASDAQ:XNCR) Stock Position Lifted by Vanguard Group Inc.

Vanguard Group Inc. lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 5.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 8,017,366 shares of the biopharmaceutical company’s stock after acquiring an additional 418,040 shares during the period. Vanguard Group Inc. owned 0.11% of Xencor worth $184,239,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in Xencor during the 4th quarter valued at about $2,329,000. Barclays PLC boosted its holdings in shares of Xencor by 100.7% in the third quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company’s stock valued at $3,128,000 after acquiring an additional 78,066 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Xencor by 16.5% during the fourth quarter. Principal Financial Group Inc. now owns 340,145 shares of the biopharmaceutical company’s stock valued at $7,817,000 after acquiring an additional 48,229 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Xencor by 7.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 626,988 shares of the biopharmaceutical company’s stock worth $12,609,000 after purchasing an additional 40,788 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in Xencor in the third quarter worth approximately $540,000.

Analyst Ratings Changes

Several equities analysts have recently issued reports on XNCR shares. StockNews.com cut Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th. Wells Fargo & Company lowered their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Xencor has a consensus rating of “Moderate Buy” and an average target price of $34.38.

Xencor Stock Performance

XNCR opened at $8.69 on Monday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm has a market cap of $612.31 million, a PE ratio of -2.72 and a beta of 0.90. The business has a fifty day simple moving average of $14.51 and a 200-day simple moving average of $19.68. Xencor, Inc. has a fifty-two week low of $8.45 and a fifty-two week high of $27.24.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. The business had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. As a group, equities analysts predict that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.